

Curriculum Vitae
Dipnarine Maharaj

PERSONAL

Name: Dipnarine Maharaj

Office Address: South Florida Bone Marrow/Stem Cell
Transplant Institute,
Bethesda Health City, Suite 600
10301 Hagen Ranch Road
Boynton Beach FL 33437
Tel: (561) 752 5522

Internet Address: dmaharaj@bmscti.org

Citizenship: British/U.S.

PRESENT ACADEMIC RANK AND POSITION

Director,
South Florida Bone Marrow Stem Cell Clinical
and Research Institute.
Bethesda Health City, Suite 600
10301 Hagen Ranch Road
Boynton Beach FL 33437
Tel: (561) 752 5522

Active, Department of Internal medicine
Division of Hematology/Oncology
Bethesda Memorial Hospital
Boynton Beach, FL 33437

Date: 10/2022

HIGHER EDUCATION

<u>Institution:</u> Presentation College, Trinidad, Cambridge University, England	G.C.E. (with distinction)	1973
University of Glasgow Medical School, Scotland	M.B. Ch.B.*	1978
University of Glasgow Medical School, Scotland	M.D.** (Doctorate in Medicine)	1990

* Medical Doctor (U.S. Equivalent is M.D. Degree)

** Research Degree awarded to senior medical doctors following submission of a thesis for research work of great distinction .

INTERNSHIP/RESIDENCY/FELLOWSHIP

University of Glasgow Medical School Western Infirmary, Royal Infirmary, Glasgow, Scotland	*Internship (Med. & Surg.) House Officer	1978-1979
University of Glasgow Medical School Royal Infirmary, Glasgow, Scotland	*Residency (Int. Med.) Senior House Officer	1979-1983
University of Glasgow Medical School Royal Infirmary, Glasgow, Scotland	*Fellowship (Hem/Onc) Registrar Lecturer (Instructor)* in Medicine	1983-1985

* **Equivalent in United States**

CERTIFICATION

Internal Medicine:

Examination for Membership of the Royal College of the Physicians of the United Kingdom: Passed 1982

Sub-Specialty:

Membership of the Royal College of Pathologists (Hematology/Oncology) 1985

Accreditation in Hematology with specialization in Oncology and Bone Marrow Transplantation by the Joint Committee on Higher Medical Training of the Royal Colleges of the United Kingdom: 1986 (Certificate issued 1990)

Fellowship of the Royal College of Physicians of Edinburgh: 1990

Fellowship of the Royal College of Physicians of Glasgow: 1993

Fellowship of the Royal College of Pathologists of the United Kingdom: 1996

Fellowship of the American College of Physicians: 2000

MEDICAL LICENSURE

Certification of satisfactory completion of medical training with a full and unrestricted registration to practice medicine by the General Council of the United Kingdom: Principal List Registration Number: 23381039 (Inactive)

Full and Unrestricted Licensure of the Florida Board of Professional Regulation and Licensure: License Number: ME 0060567

Full and Unrestricted Licensure of the Oklahoma State Board of Medical Licensure and Supervision: License Number: 17261(Inactive)

Full and Unrestricted Licensure of the University of the State of New York: License Number: 196556-1 (Inactive)

Educational Commission for Foreign Medical Graduates
Certificate Number: 370-324-6

PREVIOUS PROFESSIONAL POSITIONS AND APPOINTMENTS

Academic Institutions:

University of Glasgow Medical School Royal Infirmary, Glasgow, Scotland	*Fellowship (Heme/Onc) Senior Registrar Lecturer (Assistant Professor)* in Medicine	1985-1986
University of Newcastle-upon-Tyne Medical School, England Memorial Hospital, Darlington	*Attending Physician (Hem/Onc/Med) Consultant Physician	1986-1990
University of Miami School of Medicine/ Jackson Memorial Medical Center	Associate Professor of Medicine Associate Professor of Pathology Clinical Director Deed Club Bone Marrow Transplant Program	1990- 1993
Bone Marrow/Stem Cell Transplant Institute (ECOG Affiliate of H.Lee Moffitt Cancer Center at Univ. of South Florida) Florida Medical Center/North Ridge Medical Center	Director	1994 - 1998
South Florida (Formerly Bethesda) Bone Marrow/Stem Cell Transplant Institute. Maharaj Institute of Immune Regenerative Medicine	Medical Director	1997- Present

* **Equivalent in United States**

EDUCATION-TEACHING

<u>University of Glasgow Medical School:</u>	1979-1986
<p>Lectures to 3rd, 4th, and final year medical students on Topics in Internal Medicine/Hematology/Bone Marrow Transplantation; Clinical Seminars to small groups of Medical students in 3rd to final year.</p> <p>Lectures to postgraduate physicians preparing for certification in Internal Medicine by the Royal College of Physicians of the United Kingdom.</p>	
<u>University of Newcastle on Tyne:</u>	1986-1990
<p>Lectures to 3rd, 4th, and final year medical students on Topics in Internal Medicine/Hematology/Bone Marrow Transplantation; Clinical Seminars to small groups of Medical students in final year.</p> <p>Lectures to postgraduate physicians preparing for Certification in Internal Medicine by the Royal College of Physicians of the United Kingdom and the Royal College of Pathologists of the United Kingdom.</p> <p>Monthly lectures on Hematology/Bone Marrow Transplantation to the Association of Northern Regional Hematologists and University of Newcastle on Tyne Postgraduate Education Department.</p>	
<u>University of Miami School of Medicine:</u>	1990 – 1993
<p>Medical Students and Residents-teaching in lectures and in small groups- topics in Hematology/ Oncology and Bone Marrow Transplantation.</p> <p>Lectures on hemolytic anemia. Eight and Ninth Annual Review Course for Certification in Internal Medicine Course. 1991, 1992</p> <p>14th Annual Oncology Update at Cedars Medical Center, Miami 1992</p> <p>Lecture: Autologous Bone Marrow Transplantation: A European Perspective and Experience.</p>	
<u>Nova Southeastern University School of Health Professions:</u>	1993-2000
<p>Medical Students -teaching in lectures and in small groups- topics in Hematology/ Oncology and Bone Marrow Transplantation.</p>	
<u>Charles E.Schmidt College of Medicine at Florida Atlantic University, Boca Raton, Florida</u>	2004-2011

Medical Students -teaching in lectures
and in small groups- topics in Hematology/ Oncology
and Bone Marrow Transplantation.

Continuing Medical Education Seminars: Topics in Bone Marrow
Transplantation presented at the following:

University of Miami/Sylvester Comprehensive Cancer Center	1991 – 1993
Highland Memorial Hospital, Rochester, New York.	1993
Holy Cross Medical Center, Fort Lauderdale, FL.	1994
Florida Medical Center, Fort Lauderdale, FL.	1994- 1997
North Ridge Medical Center, Fort Lauderdale, FL	1997-1998
Broward General Medical Center, Fort Lauderdale, Fl.	1998
Bethesda Memorial Hospital, Boynton Beach, FL.	1997-1999
Palmetto Medical Center, Miami, Fl.	1998
JFK Medical Center, Palm Beach, Fl.	1999

Student Thesis and Dissertation Advising: 1986-1999

University of Glasgow
University of Newcastle-upon-Tyne
University of Miami
Bone Marrow/Stem Cell Transplant Institute

EDUCATION-JOURNALS

Reviewer for protocols voluntarily submitted to PDQ Database of the National Cancer Institute.	1996- present
------------------------------------------------------------------------------------------------------	---------------

GRADUATE STUDENTS/POST DOCTORAL FELLOWS

Jordan Steinberg. Student at Duke University. Accepted to MD.PhD. Program at John Hopkins University.	1996- 2000
-------------------------------------------------------------------------------------------------------------	------------

**INSTITUTIONAL, DEPARTMENTAL, AND DIVISIONAL ADMINISTRATIVE
RESPONSIBILITIES, COMMITTEE MEMBERSHIPS, AND OTHER ACTIVITIES.**

Cancer Committee, Florida Medical Center	1997-1998
Cancer Committee, Bethesda Memorial Hospital	1998-2001
Library Committee, Bethesda Memorial Hospital	2004-2008

Florida Department of Health Committees:

Member, Bone Marrow Transplant Advisory Panel to Secretary of Health Chairman of BMT task force for breast cancer	1992- 1997
----------------------------------------------------------------------------------------------------------------------	------------

Certificate of Need for Bone Marrow Transplantation (Ad Hoc)	1992- 1996
--------------------------------------------------------------	------------

Organ Transplant Advisory Council Medicaid (Ad Hoc)	1996-1999
--------------------------------------------------------	-----------

Organ Transplant Advisory Council Medicaid	1999-2003
-----------------------------------------------	-----------

<u>Eastern Cooperative Oncology Group:</u>	1997
--------------------------------------------	------

Principal Investigator: Bone Marrow, Stem Cell Transplant Institute/Florida Medical Center. Affiliate of H Lee Moffitt Cancer Center

<u>Broward County Medical Association:</u>	1997-2000
--------------------------------------------	-----------

Legislative Committee

PROFESSIONAL AND SOCIETY MEMBERSHIPS

Royal Medico-Chirurgical Society of Glasgow	1982
---------------------------------------------	------

Royal Society of Medicine	1983
---------------------------	------

West of Scotland Hematology/Oncology Group	1984
--------------------------------------------	------

British Society of Hematology	1985
-------------------------------	------

Northern Regional Association of Attending Physicians	1986
-------------------------------------------------------	------

Northern Regional Association of Hematology/Oncology	1986
American Society for Clinical Oncology	1992-Present
American Society for Hematology	1992-Present
International Bone Marrow Transplant Registry/CIBMTR	1992-Present
American Society for Blood and Bone Marrow Transplantation	1993-Present
American Society of Clinical Pathologists	1993
American Association of Blood Banks	1993-Present
International Society for Hemotherapy and Graft Engineering	1994-2000
Florida Medical Association	1996-2000
American Medical Association	1996-Present
Broward County Medical Association	1997-2000
American College of Physicians-American Society of Internal Medicine	1998-Present

PRESENTATIONS AT NATIONAL MEETINGS

**IBC Conference on Bone Marrow/Stem Cell Transplantation.
Scottsdale, Arizona. October 19-20, 1998.**

Topic: Establishment of an Outpatient Bone Marrow Transplant Center.

**5th International Conference of the International Society for Hemotherapy and
Graft Engineering (ISHAGE).
Baltimore, Maryland. June 1998.**

Topic: Relationship between endogenous levels of flt3-Ligand and peripheral blood stem cell harvest yields of immature dendritic cells.

**Annual Meeting of the American Society for Blood and Bone Marrow
Transplantation.**

Miami Beach, Florida, March 1998.

Topic: 1. Predictive value of Pre-leukapheresis cell CD34⁺ levels and the efficiency of collection of peripheral blood stem cells using high volume leukapheresis.

2. Totally outpatient autologous peripheral blood stem cell transplantation (APBSCT) can be performed safely with a low risk of infections.

**Thirty-Ninth Annual Meeting of the American Society of Hematology.
San Diego, California, December 5-9, 1997.**

- Topic: 1. Totally outpatient autologous peripheral blood stem cell transplantation (APBSCT) can be performed safely with a low risk of infections.
2. Peripheral blood stem cell harvest yields of immature dendritic cells(DCs) correlate inversely with endogenous levels of flt3-Ligand.

Fifth International Blood Cell Transplantation Symposium.

Omaha, Nebraska, October 5-8, 1997,

- Topic: 1. Totally outpatient autologous peripheral blood stem cell transplantation.
2. Serum thrombopoietin levels and CD 34+ subsets.
 3. Predictive value of pre-leukapheresis CD 34+ levels and the efficiency of collection of peripheral blood stem cells.

**Thirty Third Annual Meeting of the American Society of Clinical Oncology.
Denver, Colorado, July 17-20, 1997.**

- Topic: 1. Totally outpatient autologous peripheral blood stem cell transplantation (APBSCT) for poor risk patients with chemosensitive malignancies.
2. Serum thrombopoietin (TPO) levels correlate with CD34⁺ subsets predictive of rapid platelet recovery (PR) post-autologous peripheral blood stem cell transplant.

**Thirty-Eighth Annual Meeting of the American Society of Hematology.
Orlando, Florida, December 6-10, 1996.**

- Topic: 1. Endogenous levels of Thrombopoietin (TPO) in patients undergoing chemotherapy/G-CSF mobilized peripheral blood stem cell harvests followed by myeloablative chemotherapy and transplant.
2. The role of flt3-LIGAND (flt3L), Interleukin-6 (IL-6) and Stem Cell Factor (SCF) in Chemotherapy-induced marrow aplasia and flt3L as an indicator of CD34⁺ progenitors in harvest collection for autologous peripheral blood progenitor cell transplant (APBPCT).
 3. Serum Thrombopoietin (TPO) levels correlate with CD34⁺ subsets predictive of rapid platelet recovery (PR) post autologous peripheral blood stem cell transplant (APBSCT) and may optimize the timing of PBSC harvest.

2th International Conference of the International Society for Hematotherapy and Graft Engineering (ISHAGE). Vancouver, Canada. June 1998.

- Topic 1. Large volume Leukapheresis in patients with prior granulocyte colony-stimulating factor/chemotherapy mobilization of peripheral blood stem cells.

2. Serum Granulocyte Colony-stimulating factor levels in patients undergoing Granulocyte Colony-stimulating factory/chemotherapy mobilized peripheral stem cell harvest and predictors of neutrophil and platelet recovery.

**Thirty-Sixth Annual Meeting of the American Society of Hematology.
Nashville, Tennessee, December 2-6, 1994.**

Topic: 1. Serum G - CSF levels in patients undergoing G -CSF/Chemotherapy mobilized peripheral stem cell harvest.

**Thirty-Fifth Annual Meeting of the American Society of Hematology.
St Louis, Missouri, December 5-9, 1994.**

- Topic: 1. Chemotherapy and G-CSF mobilized peripheral blood leukocytes possess CD34+ stem cells and are sufficient for autologous hematopoietic engraftment.
2. Chemotherapy and G-CSF primed peripheral blood CD34 positive stem cells which provide hemopoietic reconstitution after high dose chemotherapy contain a subset of HLA-DR negative, CD38 negative cells.
 3. Chemotherapy/G-CSF primed peripheral blood stem cells alone are sufficient for rapid hematopoietic reconstitution of platelets and myeloid cells after myeloablative chemotherapy.

PRESENTATIONS AT INTERNATIONAL MEETINGS

**Scientific Meeting of British Society for Hematology
Cambridge, England, March 1990.**

- Topic: 1. Autologous bone marrow transplantation for poor prognosis non-Hodgkins lymphoma in first remission.
2. Autologous bone marrow transplantation in adult acute lymphoblastic leukemia without purging or cryopreservation.

**North of England Association of Clinical Pathologists
Newcastle-upon-Tyne , England, November 1986**

Topic: Trace metal retention in patients undergoing plasma exchange with albumin replacement solutions.

**Combined meeting of the British Society for Hematology and the Netherlands Society for Hematology.
Antwerp, Belgium, October 1986**

Topic: Aluminum in Albumin Solutions: A study in patients undergoing plasma with albumin solutions.

**The Scottish Society for Experimental Medicine
Edinburgh, Scotland, October 1986**

Topic: Aluminum retention in patients undergoing plasma exchange due to administration of albumin replacement solutions.

**The British Blood Transfusion Society Annual Meeting
London, England, September 1986**

Topic: 1. The opsonic function of fibronectin.
2. Aluminum in Blood Products.

**The Scottish Society for Immunology
Edinburgh, Scotland, May 1986**

Topic: Fibronectin an opsonin.

**The Society of Radiology 31st Annual General Meeting
Los Angeles, California, June 1984**

Topic: Bone Scan appearances following bone marrow biopsy.

**The 25th Annual General Meeting of the British Society for Hematology
London, England, April 1984**

Topic: Autologous bone marrow transplantation in first remission of acute myeloid leukemia.

**The Scottish Society of Renal Physicians
Edinburgh, Scotland, October 1983**

Topic: Folate toxicity in patients on CAPD.

**The Pathological Society of Great Britain and Ireland
Glasgow, Scotland, July 1980**

Topic: Oncolytic cystadenomata of the trachea and larynx.

INTRAMURAL PRESENTATIONS

Bethesda Memorial Hospital:

1. Weekly Tumor Board Conference
2. Weekly Bone Marrow/Stem Cell Transplant Conference
3. Department of Medicine Monthly Grand Rounds

CLINICAL PRACTICE, INTERESTS, AND ACCOMPLISHMENTS

1. Development of a patient focused healthcare delivery model of outpatient bone marrow/ stem cell transplantation with the emphasis on providing high quality care, reducing general morbidity and mortality and specifically related to nosocomial infections, improving quality of life and reducing costs associated with bone marrow transplantation.

2. Development of bone marrow transplant programs in University as well as community settings.
3. Identification of albumin solutions as a source of aluminium toxicity in patients with impaired renal function and devised method to remove trace metal contamination of albumin solutions which prevented further aluminium toxicity from this source.
4. Honors, Awards and Fellowships.
 - British Council Scholarship in Medicine (1974)
 - Certificates of Merit in Internal Medicine, Surgery, Hematology, Geriatrics (1976)
 - Macleod Medal and Prize in Medicine and Surgery (1977)
 - Traveling Fellow, Royal College of Physicians of Edinburgh (1986)
 - Myre Sim Traveling Fellow, Royal College of Physicians of Edinburgh (1990)

RESEARCH INTERESTS

Research Performed (Co-Investigator)

- (1) 1985: Scottish Research Council
Principal Investigator: Dr. J. Lackie
Department of Cell Biology
University of Glasgow
- (2) 1985: Scottish Research Council
Principal Investigator: Dr. G.S. Fell
Department of Biochemistry
University of Glasgow
- (3) 1985: Leukemia Research Fund
Principal Investigator: Dr. Alan K. Burnett
University of Glasgow
- (4) 1986: Leukemia Research Fund
Principal Investigator: Dr. S. Proctor
University of Newcastle-upon-Tyne.
- (5) 1985-1990: Medical Research Council .
 - I. UKALL Xth
Principal Investigator: Dr. J. Chessels
 - II. AML-Xth Adults
Principal Investigator: Dr. A.K. Burnett
 - III. CML
Principal Investigator: Dr. N.C. Allan

- 6) 1990- 1993: Sylvester Cancer Center Research:
Principal or Co-Investigator.
- I. Mobilization of peripheral blood hematopoietic stem cells by high dose chemotherapy with G-CSF and GM-CSF.
 - II. N-Acetylcysteine for the prevention of chemotherapy- induced alopecia
 - III. High dose Cytoxan, Thiotepa, Carboplatin and G-CSF primed peripheral blood stem cells in women in stage III or IV breast cancer following induction therapy with Adriamycin, 5-Fluorouracil and Methotrexate.
 - IV. Adjuvant Cyclophosphamide, Adriamycin and 5-Fluorouracil followed by high dose Cyclophosphamide, Thiotepa, Carboplatin and G-CSF primed peripheral blood progenitor stem cells in women with stage II/III breast cancer.
 - V. Treatment of patients with poor prognosis germ cell tumors or relapsed patients with high doses Ifosfamide, Carboplatin, Etoposide and G-CSF primed peripheral blood progenitor stem cells.
 - VI. Autologous bone marrow and stem cell transplantation in patients with acute non-lymphocytic leukemia.
 - VII. V Beta TcR expression in BMT patients: Monitoring of the ablation and reconstitution of human T-cell compartment pre and post-transplant.
 - VIII. Autologous bone marrow and stem cell transplantation for patients with Hodgkin's disease, resistant to conventional chemotherapy and radiotherapy.
 - IX. Autologous bone marrow and stem cell transplantation for patients with non-Hodgkin's

lymphoma resistant to both conventional chemo and radiotherapy.

- (7) 1992-1993 Characterization and Stimulation of CD34+ cells from umbilical cord blood.
Principal Investigator: Dipnarine Maharaj
- (8) 1992-1993 Immunex Corporation: High dose chemotherapy with BEAC and recombinant GM--CSF rescue in non-Hodgkin's lymphoma.
Principal Investigator: Dipnarine Maharaj
- (9) 1992-1993 American Cancer Society and NASA Research Utilization: Development of an immunoaffinity device for harvesting CD34+ stem cells from bone marrow and peripheral blood.
Principal Investigator: Dipnarine Maharaj
- (10) 1996-1998 Immunex Corporation: High dose chemotherapy with Mitoxantrone and Melphalan in patients with breast cancer. Principal Investigator: Dipnarine Maharaj
- (11) 1997-1998 Genentech: Phase I multi-center study of recombinant thrombopoietin in patients with delayed platelet recovery following bone marrow transplantation.
- (12) 1997-1998 Amgen: Multi-center study of multiple cycles of high dose chemotherapy and stem cell transplant for patients with breast cancer.
- (13) 1999-2004 Biomira: Multi-center study of theratope breast cancer vaccine for patients with metastatic breast cancer.
- (14) 1999-2004 Maxim: Low dose IL-2 for immunotherapy in patients with Acute Myeloid Leukemia following bone marrow transplantation.
- (15) 2004-Present Daphne Seybolt Culpepper Foundation: Cell sorting and Molecular Analysis, linking Genotype for Detection and Confirmation of minimal Disease in Multiple Myeloma.
- (16) 2004- 2011 Genzyme: Compassionate Use Protocol For The Use of AMD3100 to Mobilize Peripheral Blood Stem Cells For Collection and Transplantation.

- (17) 2007 Coley -Bankhead Foundation:Cell sorting and Molecular Analysis for Detection and of minimal Disease in Hematologic Malignancies
- (18) 2008- Present Life Extension Foundation:
FDA IND Phase I/II Study For the Use of White Blood Cells From Healthy Donor-participants To Treat Subjects With Solid Cancers.
- (19) 2015 – Present E. Lynn Foundation:
FDA IND Phase I/II Study For The Evaluation of the safety and efficacy of fresh frozen plasma from young healthy donors who have received granulocyte colony stimulating factor (GCSF) to ameliorate frailty and enhance the immune risk profile in older individuals.

COMMUNITY SERVICE

Numerous Varied Voluntary Activities In The Following Organizations:

1. Broward County Medical Association
2. American Cancer Society Relay for Life
3. Local Chapter of the Leukemia Society

BIBLIOGRAPHY

Published Articles

- (1) **Maharaj D**, McDonald GA, Dobie JW. **Splenectomy and Blackwater Fever.** British Journal of Hematology 51:4:663-665, 1982.
- (2) **Maharaj D**, Erskine JG. **Plasma exchange in patients with circulating anticoagulants.** Apheresis Bulletin 2:2:25-31, 1984.
- (3) McKillop JH, **Maharaj D**, Boyce BF, Fogelman I. **Bone scan appearances following biopsy of bone and bone marrow.** Radiology 153:1:241-242, 1984.
- (4) Burnett AK, Tansey P, **Maharaj D**, McKinnon S, Alcorn M, Singer CRJ, McDonald GA. **Transplantation of unpurged autologous bone marrow in acute myeloid leukemia in first remission.** Lancet 2:841:1068-1070, 1984
- (5) Burnett AK, Tansey P, **Maharaj D**, Alcorn M, McDonald GA, Robertson AG. **Autologous bone marrow transplantation in first remission of acute myeloid leukemia.** Experimental Hematology 12:15:125-127, 1984.
- (6) Leung ACT, **Maharaj D**, Henderson IS. **Excessive accumulation of folic acid in uremic patients on dialysis.** Dialysis and Transplantation 14:10:575-577, 1985.

- (7) **Maharaj D**, Walker ID, Paice B, Lawson DH. **Surreptitious ingestion of warfarin.** Practitioner 230:1412: 105-106, 1986.
- (8) Fell GS, **Maharaj D**. **Trace metal contamination of albumin solutions used for plasma exchange.** Lancet 2:8504:467-468, 1986.
- (9) **Maharaj D**, Walker ID, McEwan HP, Nisbet CE, Erskine JG. **Co-incident Von Willebrand's disease and immune thrombocytopenia in pregnancy - Treatment with high dose intravenous immunoglobulin.** Clinical and Laboratory Hematology 8:3:277-231, 1986.
- (10) **Maharaj D**. **Autoimmune hemolytic anemia associated with rheumatoid arthritis and paroxysmal nocturnal hemoglobinuria.** Acta hematologica. 75:4:241-242, 1986.
- (11) **Maharaj D**, Dolan G. **Acute Myeloblastic Leukemia associated with solitary plasmacytoma of the ilium.** Postgraduate Medical Journal 62:734:1131-1133, 1987
- (12) **Maharaj D**, Fell GS, Boyce BF, Ng JP, Smith GD, Boulton-Jones JM, Cumming RLC, Davidson JF. **Aluminum bone disease in patients receiving plasma exchange with contaminated albumin.** British Medical Journal 295: 6600:693-696, 1987.
- (13) **Maharaj D**, McKillop JH. **Use of intravenous immunoglobulin in severe refractory idiopathic immune thrombocytopenia.** Journal of the Royal Society of Medicine 80:10:652-654, 1987
- (14) **Maharaj D**, Baba AA. **Hypocalcaemia in pernicious anaemia and auto-immune hemolytic anaemia.** Postgraduate Medical Journal 64:747:61-62, 1988.
- (15) Proctor SJ, Carey P, Jackson G, Stark A, Finney R, Saunders P, Summerfield G, **Maharaj D**, Youart A. **Improvement of platelet counts in steroid-unresponsive idiopathic immune thrombocytopenic purpura after short course therapy with recombinant α -2b-interferon.** Blood 74:6:1894-1898, 1989.
- (16) Carey PJ, Proctor SJ, Taylor P, Hamilton PJ on behalf of members of the Northern Regional Bone Marrow Transplant Group: Abela M, Cartner R, Chandler JC, Condie P, Evans RGB, Finney R, Galloway JJ, Goff D., Hargrave S, Hendrick A, Jackson GH, L. Kay, Kesteven P, Lennard A, Lloyd H, Lucraft H, **Maharaj D**, O'Brien H, Qureshi M, Reid MM, Saunders P., Summerfield G, Tinegate H, West N, Youart A. **Autologous Bone Marrow Transplantation for High-Grade Lymphoid Malignancy Using Melphalan/Irradiation Conditioning Without Marrow Purging or Cryopreservation.** Blood 77:7:1593-1598, 1991.
- (17) **Maharaj D**, Riley R, Albarracin C, Phillips J. **Serum G-CSF levels and predictors of neutrophil and platelet recovery in patients undergoing G-CSF/chemotherapy mobilized peripheral stem cell harvest.** Leukemia 9:1:113-117,1995
- (18) **Maharaj D**, Steinberg J, Gouvea JV, Gieser PW .**Changes in Endogenous TPO Levels during mobilization chemotherapy are predictive of CD34⁺ megakaryocyte progenitor yield and identify patients at risk of delayed platelet engraftment post PBPC transplant.** Bone Marrow Transplantation 23:539-548, 1999
- (19) Nash R, Kurzrock R, Di Persio J, Vose J, Linker C, **Maharaj D**, Nademanee AP, Negrin R, Nimer S, Shulman H, Ashby M, Jones D, Appelbaum R, Champlin R. **A Phase I Trial of Recombinant Human Thrombopoietin in Patients with Delayed Platelet Recovery After Hematopoietic Stem Cell Transplantation.** Biology of Blood and Bone Marrow Transplantation 6:25-34, 2000.

- (20) Reece DE, Bredeson C, Perez WS, Jagannath S, Zhang MJ, Balle KK, Elfenbein GJ, Freytes CO, Gale RP, Gertz MA, Gibson J, Gira SA, Keating A, Kyle RA, **Maharaj D**, Marcellus D, McCarthy PL, Milone GA, Nimer SD, Pavlovsky S, To LB, Weisforf DJ, Wiernik F, Wingard JR, Vesole DH. **Autologous Stem Cell Transplantation in Multiple Myeloma Patients < 60 Versus >60 Years of Age.** Bone Marrow Transplant 32:1135-1143, 2003.
- (21) Passweg JR, Walker I, Sobocinski KA, Rio B, Litzow MR, Carreras , Szydlo R, Bolwell BJ, Ilhan O, Seiter K, **Maharaj D**, Pasquini R, Carabasi MH, Kolb HJ, Gale RP, Schouten HC, Cornelissen JJ, Goldman J, Gratwohl A, Montserrat E, Klein JP, Horowitz MM, Gira S for the Chronic Leukemia Working Committee of the International Bone Marrow Transplant Registry (IBMTR). **Validation and extension of the EBMT risk score for patients with chronic myeloid leukemia (CML) receiving allogeneic hematopoietic stem cell transplants.** Br J of Hematol 125:613-620, 2004.
- (22) Scott Baker K, Loberiza FR, Yu H, Cairo MS, Bolwell BJ, Bujan-Boza WA, Camitta BM, Garcia JJ, Ho WG, Liesveld JL, **Maharaj D**, Marks DI, Schultz KR, Wiernik P, Zander AR, Horowitz MM, Keating A, Weisdorf DJ. **Outcome of ethnic minorities with Acute or chronic leukemia treated with hematopoietic stem cell transplantation in the United States.** Journal of Clinical Oncology 23(28): 7032-7042, 2005
- (23) Parameswaran H, Carreras J, Zhang MJ, Gale RP, Bolwell BJ, Bredeson CN, Burns LJ, Cairo MS, Freytes CO, Goldstein SC, Hale GA, Inwards DJ, LeMaistre CF, **Maharaj D**, Marks DI, Schouten HC, Slavin S, Vose JM, Lazarus HM, van Besien K. **Allogeneic Transplants in Follicular Lymphoma: Higher Risk of Disease Progression after Reduced-Intensity Compared to Myeloablative Conditioning.** Biology of Blood and Marrow Transplantation 14 (2): 236-245, 2008
- (24) Bashley A, Waleska PS, Zhang MJ, Anderson KC, Ballen K, Berenson JR, Bik To L, Fonseca R, Freytes CO, Gale RP, Gibson J, Giralt SA, Kyle RA, Lazarus HA, **Maharaj D**, McCarthy PL, Milone DA, Nimer S, Pavlovsky S, Reece DE, Schiller G, Vesole DH, Hari P, Plasma Cell Disorders Working Committee. **Comparison of Twin and Autologous Transplants for Multiple Myeloma.** Biology of Blood and Marrow Transplantation 14 (10): 1118-1124, 2008
- (25) Lazarus HM, Carreras J, Boudreau C, Loberiza FR, Armitage JO, Bolwell BJ, Freytes CO, Gale RP, Gibson J, Hale GA, Inwards DJ, LeMaistre CF, **Maharaj D**, Marks DI, Miller AM, Pavlovsky S, Schouten H, van Besien K, Vose JM, Bitran JD, Khouri I, McCarthy PL, Yu H, Rowlings P, Serna DS, Horowitz MM, Rizzo D. **Influence of Age and Histology on Outcome in Adult Non-Hodgkin Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT): A Report from The Center for International Blood & Marrow Transplant Research (CIBMTR).** Biology of Blood and Marrow Transplantation 14 (12): 1323-1333, 2008
- (26) Fenske Timothy S., Hari PN, Carreras J, Zhang MJ, Kamble RT, Bolwell BJ, Cairo MS, Champlin RE, Chem YB, Freytes CO, Gale RP, Hale GA, Ilhan O, Houry HJ, Lister J, **Maharaj D**, Marks DI, Munker R, Pecora AL, Rowlings PA, Shea TC, Stiff P, Wiernik PH, Winter JN, Rizzo JD, van Besien K, Lazarus HM, Vose JM, **Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma.** Biology of Blood and Marrow Transplantation 15 (11): 1455-1464, 2009

- (27) Scott Baker K., Davies SM, Majhail NS, Hassebroek A, Klein JP, Ballen KK, Bigelow CL, Frangoul HA, Hardy CL; Bredeson C, Dehn J, Friedman D, Hahn T, Hale G, Lazarus HM, LeMaistre CF, Loberiza F, **Maharaj D**, McCarthy P, Setterholm M, Spellman S, Trigg M, Maziarz RT, Switzer G, Lee SJ, Rizzo JD. **Race and Socioeconomic Status Influence Outcomes of Unrelated Donor Hematopoietic Cell Transplantation** *Biology of Blood and Marrow Transplantation*, 15 (12): 1543-1554, 2009
- (28) Kalaycio ME, Kukreja M, Woolfrey AE, Szer J, Cortes J, Maziarz RT, Bolwell BJ, Buser A, Copelan E, Gale RP, Gupta V, **Maharaj D**, Marks DI, Pavletic SZ, Horowitz MM, Arora M, **Allogeneic hematopoietic cell transplant for prolymphocytic leukemia. Biology of Blood and Marrow Transplantation**, 16 (4): 543-547, 2010.
- (29) McCollum M, Ma Z, Cohen E, Leon R, Tao R, Wu JY, **Maharaj D**, Wei J, **Post-MPTP Treatment with granulocyte colony stimulating factor improves nigrostriatal function in the mouse model of Parkinson's disease.** *Molecular Neurobiology* 41 (2-3): 410-419, 2010.
- (30) Vogl DT, Wang T, Perez WS, Stadtmauer EA, Heitjan DF, Lazarus HM, Kyle RA, Kamble R, Weisdorf D, Roy V, Gibson J, Ballen K, Holmberg L, Bashey A, McCarthy PL, Freytes C, **Maharaj D**, Maiolino A, Vesole D, Hari P, **Effect of Obesity on Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation**, 2011: 1-10.
- (31) Akpek G, Pasquini MC, Logan B, Agovi M-A, Lazarus HM, Marks DI, Bornhaeüser M, Ringdén O, Maziarz RT, Gupta V, Popat U, **Maharaj D**, Bolwell J, Rizzo JD, Ballen KK, Cooke KR, McCarthy PL, Ho VT, **Effects of spleen status on early outcomes after hematopoietic cell transplantation.** *Bone Marrow Transplant.* 2012 Dec 10. doi: 10.1038/bmt.2012.249.
- (32) Pulsipher MA, Chitphakdithai P, Logan BR, Shaw BE, Wingard JR, Lazarus HM, Waller EK, Seftel M, Stroncek DF, Lopez AM, **Maharaj D**, Hematti P, O'Donnell PV, Loren AW, Leitman SF, Anderlini P, Goldstein SC, Levine JE, Navarro WH, Miller JP, Confer DL. **Toxicities of Unrelated Bone Marrow Versus Peripheral Blood Stem Cell Donation: Results of a Prospective Trial From The NMDP.** *Blood*, 2013 Jan 3;121(1):197-206.
- (33) Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS, Gale RP, Gibson J, Hale GA, Hari PN, Hsu JW, Inwards DJ, Kamble RT, Klein A, **Maharaj D**, Marks DI, Rizzieri DA, Savani BN, Schouten HC, Waller EK, Wirk B, Laport GG, Montoto S, Maloney DG, Lazarus HM. **Impact of Pretransplant Conditioning Regimens on Outcomes of Allogeneic Transplantation for Chemotherapy-Unresponsive Diffuse Large B cell Lymphoma and Grade 111 Follicular Lymphoma. Biology of Blood & Marrow Transplantation**, 2013 19(5):746-753.
- (34) Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS, Gale RP, Gibson J, Hale GA, Hari PN, Hsu JW, Inwards DJ, Kamble RT, Klein A, **Maharaj D**, Marks DI, Rizzieri DA, Savani BN, Schouten HC, Waller EK, Wirk B, Lazarus HM. **Allogeneic Hematopoietic Cell Transplantation For Chemotherapy-Unresponsive Mantle Cell Lymphoma: A Cohort Analysis from the CIBMTR. Biology of Blood & Marrow Transplantation**, 2013 19(4):625-631
- (35) Maziarz RT, Wang Z, Zhang M-J, Bolwell BJ, Chen AI, Fenske TS, Freytes CO, Gale RP, Gibson J, Hayes-Lattin BM, Holmberg L, Inwards DJ, Isola LM, Khoury HJ, Lewis VA,

- Maharaj D**, Munker R, Phillips GL, Rizzieri DA, Rowlings PA, Saber W, Satwani P, Waller EK, Maloney DG, Montoto S, Laport GG, Vose JM, Lazarus HM, Hari PN. **Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement.** *Br J Haematol.* 2013.162(5):648-656
- (36) Foran JM, Pavletic SZ, Logan BR, Agovi-Johnson MA, Pérez WS, Bolwell BJ, Bornhäuser M, Bredeson CN, Cairo MS, Camitta BM, Copelan EA, Dehn J, Gale RP, George B, Gupta V, Hale GA, Lazarus HM, Litzow MR, **Maharaj D**, Marks DI, Martino R, Maziarz RT, Rowe JM, Rowlings PA, Savani BN, Savoie ML, Szer J, Waller EK, Wiernik PH, Weisdorf DJ **Unrelated donor allogeneic transplantation after failure of autologous transplantation for acute myelogenous leukemia: a study from the Center for International Blood and Marrow Transplantation Research.** *Biol Blood Marrow Transplant* 2013 19(7):1102-1108
- (37) Schouten HC, Hale GA, Holmberg LA, Sureda A, Freytes CO, Maziarz RT, Inwards DJ, Gale RP, Gross TG, Cairo MS, Costa LJ, Lazarus HM, Wiernik PH, **Maharaj D**, Laport GG, Montoto S, Hari PN **Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma.** *J Clin Oncol* 2013 31(25):3100-3109
- (38) Akpek G, Pasquini MC, Logan B, Agovi M-A, Lazarus HM, Marks DI, Bornhaeüser M, Ringdén O, Maziarz RT, Gupta V, Popat U, **Maharaj D**, Bolwell BJ, Rizzo JD, Ballen KK, Cooke KR, McCarthy PL, Ho VT **Effects of spleen status on early outcomes after hematopoietic cell transplantation.** *Bone Marrow Transplant* 2013 48(6):825-831
- (39) Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS, Gale RP, Gibson J, Hale GA, Hari PN, Hsu JW, Inwards DJ, Kamble RT, Klein A, **Maharaj D**, Marks DI, Rizzieri DA, Savani BN, Schouten HC, Waller EK, Wirk B, Lazarus HM **Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the Center for International Blood and Marrow Transplant Research.** *Biol Blood Marrow Transplant* 2013 19(4):625-631
- (40) Lechowicz MJ, Lazarus HM, Carreras J, Laport GG, Cutler CS, Wiernik PH, Hale GA, **Maharaj D**, Gale RP, Rowlings PA, Freytes CO, Miller AM, Vose JM, Maziarz RT, Montoto S, Maloney DG, Hari PN **Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome.** *Bone Marrow Transplant* 2014 49(11):1360-1365
- (41) Wirk B, Fenske TS, Hamadani M, Zhang M-J, Hu Z-H, Akpek G, Aljurf MD, Armand P, Ayala E, Bachanova V, Bolwell B, Cairo MS, Cashen A, Chen Y-B, Costa LJ, Farhan S, Freytes CO, Gajewski JL, Gibson J, Hale GA, Holmberg LA, Hsu JW, Inwards DJ, Kamble RT, **Maharaj D**, Maziarz RT, Munker R, Nath R, Reddy NM, Reeder CB, Rizzieri DA, Sauter CS, Savani BN, Schouten HC, Sureda A, Vose JM, Waller EK, Wiernik PH, Gale RP, Burns LJ, Saber W **Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma.** *Biol Blood Marrow Transplant* 2014 20(7):951-959
- (42) **Maharaj D**,Vianna PG,Ward W,Messina AJ, Rayborn T, Gouvea JV,Hammer RD, Cui Z. **Young donor white blood cell immunotherapy induces extensive necrosis in advanced-stage solid tumors.** *Heliyon* 3(2017) e00438
- (43) Le W, Chen B, **Maharaj D**, Cui Z. **Natural cancer-killing activity of human granulocytes.** *Integrative Cancer Science and Therapeutics* 2018. 5. 10.15761/ICST.1000263.

- (44) **Maharaj D**, Vianna P, DeCarvalho G, Pourkalbassi D, Hickey C, Gouvea J. **Molecular remission using low-dose immunotherapy for relapsed refractory Philadelphia chromosome-positive precursor B-cell acute lymphoblastic leukemia post-allogeneic stem cell transplant.** *Future Science* 2019 Apr 12; <https://doi.org/10.4155/fsoa-2019-0009>.
- (45) Schmidt S, Liu Y, Hu Z-H, Williams KM, Lazarus HM, Vij R, Kharfan-Dabaja MA, Ortí G, Wiernik PH, Weisdorf D, Kamble RT, Herzig R, Wirk B, Cerny J, Bacher U, Chaudhri NA, Nathan S, Farhadfar N, Aljurf M, Gergis U, Szer J, Seo S, Hsu JW, Olsson RF, **Maharaj D**, George B, Hildebrandt GC, Agrawal V, Nishihori T, Abdel-Azim H, Alyea E, Popat U, Sobecks R, Scott BL, Holter Chakrabarty J, Saber W. **The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era.** *Biol Blood Marrow Transplant.* 2020;26(6):1137-1143. doi:10.1016/j.bbmt.2020.02.006
- (46) **Maharaj D**, Srinivasan G, Abreu M.M., Ko M.-W., Jewett A, Gouvea J. **Molecular Remission Using Low-Dose Immunotherapy with minimal Toxicities for Poor Prognosis IGHV – Unmutated Chronic Lymphocytic Leukemia.** *Cells.* 2021. <https://dx.doi.org/10.3390/cells10010010>
- (47) **Maharaj D**, Srinivasan G, Makepeace S, Hickey C.J., Gouvea J. **Clinical Remission Using Personalized Low-Dose Intravenous Infusions of N-acetylcysteine with Minimal Toxicities for Interstitial Cystitis/Bladder Pain Syndrome.** *Journal of Personalized Medicine.* 2021. <https://doi.org/10.3390/jpm11050342>
- (48) Phelan R, Im A, Hunter RL, Inamoto Y, Lupo-Stanghellini MT, Rovo A, Badawy SM, Burns L, Eissa H, Murthy HS, Prasad P, Sharma A, Suelzer E, Agrawal V, Aljurf M, Baker K, Basak GW, Buchbinder D, DeFilipp Z, Grkovic LD, Dias A, Einsele H, Eisenberg ML, Epperla N, Farhadfar N, Flatau A, Gale RP, Greinix H, Hamilton BK, Hashmi S, Hematti P, Jamani K, **Maharaj D**, Murray J, Naik S, Nathan S, Pavletic S, Peric Z, Pulanic D, Ross R, Salonia A, Sanchez-Ortega I, Savani BN, Schechter T, Shah AJ, Smith SM, Snowden JA, Steinberg A, Tremblay D, Vij SC, Walker L, Wolff D, Yared JA, Schoemans H, Tichelli A. **Male-Specific late effects in adult hematopoietic cell transplantation recipients: A systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation.** *Transplant Cell Ther* 28(6):335.e1-335.e17, 2022
- (49) Phelan R, Im A, Hunter RL, Inamoto Y, Lupo-Stanghellini MT, Rovo A, Badawy SM, Burns L, Eissa H, Murthy HS, Prasad P, Sharma A, Suelzer E, Agrawal V, Aljurf M, Baker K, Basak GW, Buchbinder D, DeFilipp Z, Grkovic LD, Dias A, Einsele H, Eisenberg ML, Epperla N, Farhadfar N, Flatau A, Gale RP, Greinix H, Hamilton BK, Hashmi S, Hematti P, Jamani K, **Maharaj D**, Murray J, Naik S, Nathan S, Pavletic S, Peric Z, Pulanic D, Ross R, Salonia A, Sanchez-Ortega I, Savani BN, Schechter T, Shah AJ, Smith SM, Snowden JA, Steinberg A, Tremblay D, Vij SC, Walker L, Wolff D, Yared JA, Schoemans H, Tichelli A. **Male-specific late effects in adult hematopoietic cell transplantation recipients: A systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation.** *Bone Marrow Transplant* 57(7):150-1163, 2022

- (50) **Maharaj D**, Polineni G, Abreu M.M., Jewett A, Gouvea J. **Molecular Remission Using Low-Dose Immunotherapy. *NK Cells in Cancer Immunotherapy: Successes and Challenges***, Chapter 20: Editors Jewett, Anahid. ELSEVIER ACADEMIC PRESS, 2022. (IN PRESS)
- (51) Kaur K, Chen P, Ko M, Mei A, Chovatiya N, Huerta-Yeppez S, Ni W, Mackay S, Zhou J, **Maharaj D**, Malarkannan S, Jewett A. **The Potential Role of Cytotoxic Immune Effectors in Induction, Progression and Pathogenesis of Amyotrophic Lateral Sclerosis (ALS)**. *Cells*. 2022, 11, 3431. <https://doi.org/10.3390/cells11213431>

Abstracts

- (52) **Maharaj D**, Smith GD, Boyce BF. **Oncolytic cysts of the trachea and larynx**. *The Journal of Pathology* 132:2:354-355, 1980.
- (53) McKillop JH, **Maharaj D**, Boyce BF. **Bone Scan appearances following bone marrow biopsies**. *The Journal of Nuclear Medicine* 25:5:77-78, 1984.
- (54) Burnett AK, Tansey P, Alcorn M, **Maharaj D**, McDonald GA, Robertson AG. **Autologous bone marrow transplantation in first remission of acute myeloid leukemia**. *British Journal of Hematology* 58:1: 187-188, 1984.
- (55) **Maharaj D**, Fell GS, McDonald GA, Boulton-Jones JM. **Aluminum retention in patients undergoing plasma exchange due to administration of albumin replacement solutions**. *Scottish Medical Journal* 31:4:266-267, 1986.
- (56) **Maharaj D**, Fell GS. **Aluminum in blood products**. *Proceedings of the British Blood Transfusion Society* 30:2:250-252, 1987.
- (57) **Maharaj D**, Lackie JM, Gabra GS. **Opsonic function of fibronectin**. *Proceedings of the British Blood Transfusion Society* 30:2:200-202, 1987.
- (58) **Maharaj D**, Fell GS, Davidson JF. **Aluminum in albumin solutions - A study in patients undergoing plasma exchange with albumin solutions**. *British Journal of Hematology* 66:3:422-424, 1987.
- (59) Wilson C, **Maharaj D**, McCall F, Gemmell C, Imrie CW. **Can fibronectin predict the outcome of acute pancreatitis**. *British Journal of Surgery* 75:6:607-608, 1988.
- (60) MacRury SM, **Maharaj D**, Gemmell C, Paterson KR. **Changes in Phagocytic Function during improved glycaemic control**. *Diabetologia* 31:7:516-518 1988.
- (61) Proctor SJ, Jackson G, Carey P, Stark A, Finney R, Saunders P, Summerfield G, **Maharaj D**, Youart A. **Treatment of steroid-unresponsive idiopathic immune thrombocytopenic purpura with recombinant α -2b-interferon**. *British Journal of Hematology* 77:1:71-72, 1989.
- (62) Proctor SJ, Carey P, Taylor P, Hamilton PJ, Chandler JE, Finney R, **Maharaj D**, O'Brien H. **Autotransplantation in adult acute lymphoblastic leukemia without purging or cryopreservation**. *British Journal of Hematology* 74:1:51-52, 1990
- (63) Carey PJ, Taylor P, Jackson G, Proctor SJ, Chandler JE, Finney R, Hamilton PJ, **Maharaj D**, O'Brien H. **Autologous Bone Marrow Transplantation for poor prognosis Non-Hodgkins Lymphoma in first remission - lack of toxicity using**

- Melphelan +/- TB1 Conditioning without marrow cryopreservation or purging.** British Journal of Hematology 74:1:20-22, 1990.
- (64) Mylvaganam R, **Maharaj D**, O'Neill GJ, Byrnes JJ. **Flow Cytometric detection of a unique subset of CD34+ CD14+ cells in patients with acute myelogenous leukemia by a whole blood lysis technique.** Blood 78:10:458, 1991.
- (65) **Maharaj D**, Guerra ML, Smith R, Cassileth PA. **Prophylactic aerosolized amphotericin B in patients undergoing autologous bone marrow transplantation.** Blood 82:10:(Supp 1) 637a, 1993.
- (66) **Maharaj D**, Riley R, O'Neill GJ, Phillips J, Gomez O, Elia J. **Chemotherapy and G-CSF mobilized peripheral blood leukocytes possess CD34+ stem cells and are sufficient for autologous hematopoietic engraftment.** Blood 82: 10: (Suppl 1)636a, 1993.
- (67) **Maharaj D**, Ledford MR, Chatoor H, Cassileth PA. **High dose chemotherapy induced abnormal platelet function in bone marrow transplant patients.** Blood 82:10: (Suppl 1)609a, 1993.
- (68) Ledford MR, **Maharaj D**, Ucar A, Cassileth PA. **Abnormal platelet function induced by peripheral blood stem cell harvesting (PBSC) in autologous bone marrow transplant.** Blood 82:10: (Suppl 1)607a, 1993.
- (69) **Maharaj D**, Guerra M, Morrell L, Smith R, Hanlon J, Cassileth PA. **Chemotherapy/G-CSF primed peripheral blood stem cells alone are sufficient for rapid hematopoietic reconstitution of platelets and myeloid cells after myeloablative chemotherapy.** Blood 82:10: (Suppl 1)83a, 1993.
- (70) **Maharaj D**, Riley R, O'Neill JG, Phillips J, Gomez O, Elia J. **Chemotherapy and G-CSF primed peripheral blood CD34 positive stem cells which provide hemopoietic reconstitution after high dose chemotherapy contain a subset of HLA-DR negative, CD38 negative cells.** Blood 82:10: (Suppl 1)13a, 1993.
- (71) **Maharaj D**, Riley R, O'Neill GJ, Phillips J, Gomez O, Elia J. **Chemotherapy and G-CSF mobilized peripheral blood leukocytes possess a heterogeneous population of CD34 positive stem cells sufficient for autologous hematopoietic engraftment.** Journal of Cellular Biochemistry 18B: 102, 1994.
- (72) **Maharaj D**, Riley R, O'Neill GJ, Phillips J, Gomez O, Elia J. **Chemotherapy and G-CSF mobilized peripheral blood leukocytes possess a heterogeneous population of CD34 positive stem cells sufficient for autologous hematopoietic engraftment.** Journal of Cellular Biochemistry 18B: 102, 1994.
- (73) **Maharaj D**, Lewis-Ximenez L, Riley R, Albarracin C, Gomez O, O'Neill JG. **Serum G-CSF levels in patients undergoing G-CSF/Chemotherapy mobilized peripheral stem cell harvest.** Blood. 84:10:349,1994.
- (74) **Maharaj D**, Lewis-Ximenez L, Riley R, Albarracin C. **Serum Granulocyte Colony-stimulating factor levels in patients undergoing Granulocyte Colony-stimulating factor/chemotherapy mobilized peripheral stem cell harvest and predictors of neutrophil and platelet recovery.** J Haemother 4:3: 243,1995.
- (75) Lewis-Ximenez L, **Maharaj D**, J. Phillips, O'Neill JG. **Large volume Leukapheresis in patients with prior granulocyte colony-stimulating factor/chemotherapy mobilization of peripheral blood stem cells.** J Haemother 4:3:199,1995.
- (76) **Maharaj D**, Bird S, O'Neill GJ, Steinberg J, McCoy K, Kaplan J, Gouvea J, Nichol J. **Endogenous levels of Thrombopoietin (TPO) in patients undergoing**

- chemotherapy/G-CSF mobilized peripheral blood stem cell harvests followed by myeloablative chemotherapy and transplant. Blood 86:10 (Suppl 1): 401a, 1996.
- (77) **Maharaj D**, Greenberg A, Steinberg J, O'Neill GJ, McCoy K, Kaplan J, Gouvea J, Lyman SE. **The role of flt3-LIGAND (flt3L), Interleukin-6 (IL-6) and Stem Cell Factor (SCF) in Chemotherapy-induced marrow aplasia and flt3L as an indicator of CD34⁺ progenitors in harvest collection for autologous peripheral blood progenitor cell transplant (APBPCT).** Blood 86:10 (Suppl 1): 401a, 1996
- (78) **Maharaj D**, Byrd S, Greenberg A, Bautista D, Steinberg J, Dennis D, Melo J, Gouvea J, Bell S. **Autologous Peripheral Blood Stem Cell Transplantation (APBSCT) in the totally outpatient setting for poor risk patients with Chemosensitive Malignancies.** Blood 86:10 (Suppl 1): 401a, 1996
- (79) **Maharaj D**, Steinberg J, O'Neill GJ, McCoy K, Gouvea J, Nichol J. **Serum Thrombopoietin (TPO) Levels Correlate with CD34⁺ Subsets Predictive of Rapid Platelet Recovery (PR) Post Autologous Peripheral Blood Stem Cell Transplant (APBSCT) and may Optimize the Timing of PBSC Harvest.** Blood 86:10 (Suppl 1):401a, 1996
- (80) **Maharaj D**, Steinberg J, O'Neill GJ, Morrissey J, Gouvea J, Nichol: **Serum thrombopoietin (TPO) levels correlate with CD34⁺ subsets predictive of rapid platelet recovery (PR) post-autologous peripheral blood stem cell transplant (APBSCT):** Proc Am Soc Clin Oncol 16:99a, 1997
- (81) **Maharaj D**, Byrd S, Gouvea J, Carpenter S, Greenberg A., Steinberg J, Dennis D, Melo J, Morrissey J, Bell S: Proc Am Soc Clin Oncol 16:98a, 1997 **Totally outpatient autologous peripheral blood stem cell transplantation (APBSCT) for poor risk patients with chemosensitive malignancies**
- (82) **Maharaj D**, Wagner P, Steinberg J, O'Neill GJ, McCoy K, Kaplan J, Gouvea J, Maraskovsky E, Lyman SE. **Peripheral blood stem cell harvest yields of immature dendritic cells(DCs) correlate inversely with endogenous levels of flt3-LIGAND (flt3L).** Blood 90:212a, 1997
- (83) **Maharaj D**, Gouvea J, Greenberg A., Carpenter S, Bell S, Knisely P, McCoy K, O'Neill GJ: **Totally outpatient autologous peripheral blood stem cell transplantation (APBSCT) can be performed safely with a low risk of infections.** J of ASBMT :17, 1998 (#66)
- (84) O'Neill GJ, Gouvea J, McCoy K, Steinberg J, Bell S, Gomer D, Carpenter S, **Maharaj D: Predictive value of Pre-leukapheresis cell CD34⁺ levels and the efficiency of collection of peripheral blood stem cells using high volume leukapheresis .** J of ASBMT:17,1998.(#21)
- (85) **Maharaj D**, Wagner P, Steinberg J, O'Neill GJ, McCoy K, Kaplan J, Gouvea J, Maraskovsky E, Lyman SE. **The relationship between peripheral blood stem cell harvest yields of immature dendritic cells(DCs) and endogenous levels of flt3-LIGAND (flt3L),.** J Hematother 7:277, 1998.
- (86) **Maharaj D**, Gouvea JV, Steinberg J, Gieser PW. **Low incidence of breast cancer cell contamination in peripheral blood progenitor cell(PBPC) products collected with cytoxan/VP 16 mobilization and large volume leukapheresis to achieve > 10x10⁶CD34 cells/Kg:** Proc Am Soc Clin Oncol 18:63a, 1999.

- (87) Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS, Gale RP, Gibson J, Hale GA, Hari PN, Hsu JW, Inwards DJ, Kamble RT, Klein A, **Maharaj D**, Marks DI, Rizzieri DA, Savani BN, Schouten HC, Waller EK, Wirk B, Laport GG, Montoto S, Maloney DG, Lazarus HM. **Impact of pretransplant conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B-cell lymphoma and grade-III follicular lymphoma.** Blood ASH 2012
- (88) Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS, Gale RP, Gibson J, Hale GA, Hari PN, Hsu JW, Inwards DJ, Kamble RT, Klein A, **Maharaj D**, Marks DI, Rizzieri DA, Savani BN, Schouten HC, Waller EK, Wirk B, Lazarus HM. **Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the CIBMTR.** Blood ASH 2012